Hemogenyx Pharmaceuticals Price: HEMO Skyrockets, Surging Below 1,200

PUBLISHED: 14 Sep 2025 @ 10:52 | Comments (0) | More info about Azeez Mustapha

Hemogenyx Pharmaceuticals Plc (LSE:HEMO) traded in a prolonged decline below the 200-trade line from April to late August before sharply rebounding at the start of September to press toward the sub-1,200 resistance.

Despite the sharp surge in the stock operations toward the 1,200 threshold, warning signs are mounting as the move follows months of suppressed trading below the 200-trade line. Such abrupt spikes often precede exhaustion phases, leaving traders vulnerable to steep reversals. Without sustained confirmation above resistance, the current rally risks turning into a short-lived over-extension trap.

Resistance Levels: 1,200, 1,300, 1,400
Support Levels: 650, 550, 450

Could HEMO Plc’s Surge Below 1,200 Face Bearish EMA-Oscillator Divergence, Signaling Reversal Risks Ahead?

The surges in the Hemogenyx Pharmaceuticals Plc shares-offering firm may appear promising, yet the bearish EMA-oscillator divergence raises concern. Without sustained confirmation above 1,200, momentum risks fading quickly, exposing traders to possible reversal traps and heightened downside volatility.

The 15-day EMA continues to maintain positive traction above the 50-day EMA, reinforcing a bullish bias. However, with the Stochastic Oscillators northbound in the overbought zone, price movement may soon consolidate, and traders should remain cautious of potential pullbacks from exhaustion pressures.

Learn from market wizards: Books to take your trading to the next

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

Follow @ItuGlobal

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.